Direct-To-Consumer Marketing of Prescription Drugs
- 1 January 2004
- journal article
- Published by Springer Nature in CNS Drugs
- Vol. 18 (2) , 69-77
- https://doi.org/10.2165/00023210-200418020-00001
Abstract
In the US and New Zealand, the past decade has seen tremendous growth in the marketing of prescription drugs directly to patients. The pharmaceutical industry has applied pressure in other countries to relax regulations governing such marketing although this has not yet been successful. While we still have much to learn about the potential impact on the public’s health of direct-to-consumer (DTC) marketing, some data are available.Keywords
This publication has 28 references indexed in Scilit:
- The price of innovation: new estimates of drug development costsJournal of Health Economics, 2003
- Accuracy of pharmaceutical advertisements in medical journalsThe Lancet, 2003
- AngelaAmerican Journal of Psychiatry, 2002
- Direct Marketing of Pharmaceuticals to ConsumersAnnual Review of Public Health, 2002
- For and against: Direct to consumer advertising is medicalising normal human experience: ForBMJ, 2002
- Direct-to-Consumer Advertising — Strengthening Our Health Care SystemNew England Journal of Medicine, 2002
- Direct-to-Consumer Advertising — Education or Emotion Promotion?New England Journal of Medicine, 2002
- Direct-to-consumer advertising: The jury is still outClinical Therapeutics, 2001
- Direct-to-consumer advertisements for prescription drugs: what are Americans being sold?The Lancet, 2001
- Direct-to the-Public Advertisement of Prescription DrugsNew England Journal of Medicine, 1988